Payers will pay a premium for demonstrated superior efficacy in a hard clinical endpoint, meaningful reduction in administration burden (infusion center visits eliminated, injection frequency reduced), or meaningful safety improvement (reduced immunogenicity leading to fewer treatment failures over multi-year use)
*Denominacin Comn Internacional (DCI)
While GLP-1 drugs are not cancer treatments, reducing this metabolic stress may have broader long-term implications
In clinical trials for its use in treating obesity, participants taking Ozempic experienced greater weight loss compared to those on a placebo
Scientific interest in the compound reflects its value as a laboratory tool only and does not constitute a claim of therapeutic, cosmetic, or clinical benefit
Gross, B., Pawlak, M., Lefebvre, P